Table 1 Characteristics of completed versus discontinued trials and published versus unpublished trials (n = 142)
From: Rates of discontinuation and non-publication of upper and lower extremity fracture clinical trials
Characteristic | Total | Trial status | Publication status | ||||
|---|---|---|---|---|---|---|---|
Discontinued (57) | Completed (85) | χ2, P | Published (71) | Unpublished (71) | χ2, P | ||
Intervention | |||||||
Pharmaceutical | 83 (58.45) | 32 (22.54) | 51 (35.92) | Pearson χ2 = 0.44, P = .93 | 46 (32.39) | 37 (26.06) | Pearson χ2 = 2.89, P = .41 |
Behavioral/dietary | 6 (4.23) | 2 (1.41) | 4 (2.82) | 2 (1.41) | 4 (2.82) | ||
Device | 30 (21.13) | 13 (9.15) | 17 (11.97) | 12 (8.45) | 18 (12.68) | ||
Procedure | 23 (16.2) | 10 (7.04) | 13 (9.15) | 11 (7.75) | 12 (8.45) | ||
Funding | |||||||
Hospital/university | 73 (51.41) | 31 (21.83) | 42 (29.58) | Pearson χ2 = 6.14, P = .11 | 34 (23.94) | 39 (27.46) | Pearson χ2 = 0.91, P = .82 |
Industry | 30 (21.13) | 10 (7.04) | 20 (14.08) | 17 (11.97) | 13 (9.15) | ||
Mixed | 29 (20.42) | 15 (10.56) | 14 (9.86) | 15 (10.56) | 14 (9.86) | ||
Other | 10 (7.04) | 1 (0.7) | 9 (6.34) | 5 (3.52) | 5 (3.52) | ||
Published | |||||||
No | 71 (50) | 45 (78.9) | 26 (30.6) | Pearson χ2 = 31.92, P < .001 | 71 (100) | 0 (0.0) | – |
Yes | 71 (50) | 12 (21.1) | 59 (69.4) | 0 (0.0) | 71 (100) | ||
Completed | |||||||
No | 57 (40.14) | 57 (100) | 0 (0.0) | – | 12 (16.9) | 45 (63.4) | Pearson χ2 = 31.92 P < .001 |
Yes | 85 (59.86) | 0 (0.0) | 85 (100) | 59 (83.1) | 26 (36.6) | ||
Enrollment; Median: 80 (IQR: 37–164) | |||||||
< 80 | 66 (46.48) | 34 (59.6) | 32 (37.6) | Pearson χ2 = 6.64, P = .01 | 24 (33.8) | 42 (59.2) | Pearson χ2 = 9.17, P = .002 |
≥ 80 | 76 (53.52) | 23 (40.4) | 53 (62.4) | 47 (66.2) | 29 (40.8) | ||